Milestone Pharmaceuticals (MIST) Cash from Operations (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Cash from Operations came in at 16053000.0 in Q1 2026, down 15.06% YoY from 18898949.96 in Q1 2025, and down 25.66% on a QoQ basis from 12775000.0 in Q4 2025.
Milestone Pharmaceuticals (MIST) Cash from Operations (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Cash from Operations data on file, last reported at 16053000.0 in Q1 2026.
- Quarterly Cash from Operations fell 15.06% year-over-year to 16053000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51142000.0 (down 51.01% YoY) and the FY2025 annual result came in at 49041000.0, down 70.0% from the prior year.
- Cash from Operations retreated to 16053000.0 in Q1 2026, from 12775000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 6053000.0 in Q2 2024 to a low of 16053000.0 in Q1 2026.
- A 5-year average of 11343235.29 and a median of 12160000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 1487.68% — and 2024, when it jumped 42.7%.
- Tracing MIST's Cash from Operations over 5 years: stood at 12862000.0 in 2022, then rose by 23.84% to 9796000.0 in 2023, then surged by 30.14% to 6843000.0 in 2024, then plunged by 86.69% to 12775000.0 in 2025, then retreated by 25.66% to 16053000.0 in 2026.
- The last three Cash from Operations figures came in at 16053000.0 (Q1 2026), 12775000.0 (Q4 2025), and 9748000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - | -22.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.71 Mn |
| Jun 30, 2026 | -22.71 Mn |
| Mar 31, 2026 | -16.05 Mn |
| Mar 31, 2026 | -16.05 Mn |
| Dec 31, 2025 | -12.78 Mn |
| Dec 31, 2025 | -12.78 Mn |
| Sep 30, 2025 | -9.75 Mn |
| Sep 30, 2025 | -9.75 Mn |
| Jun 30, 2025 | -12.57 Mn |
| Jun 30, 2025 | -12.57 Mn |
| Mar 31, 2025 | -13.95 Mn |
| Mar 31, 2025 | -13.95 Mn |
| Dec 31, 2024 | -6.84 Mn |
| Dec 31, 2024 | -6.84 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Jun 30, 2024 | -6.05 Mn |
| Jun 30, 2024 | -6.05 Mn |
| Mar 31, 2024 | -8.93 Mn |
| Mar 31, 2024 | -8.93 Mn |